 REDWOOD CITY, Calif., July 19, 2021 PRNewswire -- Nevro Corp. NYSE: NVRO, a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced receipt of FDA approval of its Senza System for the treatment of chronic pain associated with Painful Diabetic Neuropathy PDN. 